P80 Natural Essence Exerts Efficient Anti-HIV-1- as Well as Adjuvant Effects in DCs.
HIV-1
P80 natural essence
complement
dendritic cells
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
06
04
2021
revised:
18
08
2021
accepted:
26
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Dendritic cells (DCs), as well as complement, play a major role during human immunodeficiency virus 1 (HIV-1) entry and infection at mucosal sites. Together, DCs and complement are key points for understanding host defence against HIV-1 infection and for studying the impact of new drugs on the regulation of innate host-pathogen interactions and adaptive immunity. For this, we evaluated the antiviral effect of the P80 natural essence (Longan extract) on interactions of non- and complement-opsonized HIV-1 with DCs. In viability assays, we first illustrated the effects of P80 natural essence on DC function. We found that P80 concentrations above 1.5% caused increased cell death, while at concentrations between 0.5% and 1% the compound exerted efficient antiviral effects in DCs and illustrated an adjuvant effect regarding DC activation. DC maturation, as well as co-stimulatory capacity, were significantly improved by P80 natural essence via p38 MAPK phosphorylation in presence of the viral challenge independent of the opsonization pattern. These findings might be exploited for future therapeutic options to target DC subsets directly at mucosal sites by P80 natural essence and to block entry of both, non- and complement-opsonized HIV-1.
Identifiants
pubmed: 34579213
pii: vaccines9090976
doi: 10.3390/vaccines9090976
pmc: PMC8472994
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund FWF
ID : P 33510
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : P33510-B13
Pays : Austria
Références
Nature. 2010 Sep 9;467(7312):214-7
pubmed: 20829794
J Exp Med. 1998 Dec 7;188(11):2175-80
pubmed: 9841930
Mucosal Immunol. 2021 May;14(3):743-750
pubmed: 33568786
Food Chem. 2018 Aug 1;256:268-279
pubmed: 29606448
J Allergy Clin Immunol. 2021 Sep;148(3):909
pubmed: 34284045
PLoS Pathog. 2015 Jun 29;11(6):e1005005
pubmed: 26121641
Annu Rev Immunol. 2012;30:1-22
pubmed: 22136168
Carbohydr Polym. 2019 Jun 1;213:247-256
pubmed: 30879666
PLoS Pathog. 2010 Apr 29;6(4):e1000891
pubmed: 20442876
Molecules. 2011 Jul 21;16(7):6148-64
pubmed: 21778950
J Invest Dermatol. 2003 Mar;120(3):390-9
pubmed: 12603851
Cell Host Microbe. 2013 Apr 17;13(4):441-51
pubmed: 23601106
Immunol Lett. 2005 Mar 15;97(2):209-14
pubmed: 15752560
J Immunol. 2019 Jul 1;203(1):3-5
pubmed: 31209141
Virology. 2013 Feb 5;436(1):81-90
pubmed: 23158101
J Immunol. 2007 Jun 15;178(12):7840-8
pubmed: 17548622
Jpn J Infect Dis. 2016 May 20;69(3):213-20
pubmed: 26255732
Science. 2014 Sep 5;345(6201):1256070
pubmed: 25190799
Nat Rev Immunol. 2007 Apr;7(4):310-7
pubmed: 17380160
Carbohydr Polym. 2020 Feb 1;229:115475
pubmed: 31826430
Blood. 2000 Aug 1;96(3):1039-46
pubmed: 10910920
mBio. 2021 Apr 27;12(2):
pubmed: 33906927
J Allergy Clin Immunol. 2012 Dec;130(6):1368-74.e2
pubmed: 23063584
J Infect Dis. 2015 Jul 1;212(1):44-56
pubmed: 25583169
Food Sci Biotechnol. 2019 Dec 23;29(5):683-692
pubmed: 32419967
J Immunol. 2006 Nov 15;177(10):7103-13
pubmed: 17082627
Plant Biotechnol J. 2013 Aug;11(6):681-90
pubmed: 23506331